
Bryony Simmons

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3931601/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. New England Journal of Medicine, 2019, 381, 803-815.	13.9	447
2	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	3.7	370
3	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV,the, 2020, 7, e666-e676.	2.1	145
4	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. Thorax, 2020, 75, 1082-1088.	2.7	133
5	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 3379-3385.	1.3	95
6	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 3373-3378.	1.3	78
7	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BMJ, The, 2021, 372, n423.	3.0	56
8	Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. Nature Communications, 2020, 11, 5922.	5.8	55
9	Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. Aids, 2021, 35, 1657-1665.	1.0	40
10	Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. Aids, 2021, 35, 1423-1432.	1.0	31
11	Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis. The Lancet Global Health, 2019, 7, e1189-e1196.	2.9	24
12	Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Research, 2019, 4, 132.	0.9	21
13	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. Aids, 2021, 35, 205-211.	1.0	11
14	Progress towards antibiotic use targets in eight high-income countries. Bulletin of the World Health Organization, 2021, 99, 550-561.	1.5	8